Liothyronine
- Generic Name
- Liothyronine
- Brand Names
- Cytomel, Np Thyroid
- Drug Type
- Small Molecule
- Chemical Formula
- C15H12I3NO4
- CAS Number
- 6893-02-3
- Unique Ingredient Identifier
- 06LU7C9H1V
- Background
Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.
- Indication
Liothyronine is officially approved for the following indications:
In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.
...
- Associated Conditions
- Autonomy of thyroid gland, Hyperthyroidism, Hypothyroidism, Myxedema coma, Thyroid Cancer, Euthyroid Goitre, Myxedema pre-coma
- Associated Therapies
- Supplemental or replacement therapy
Actions of thyroid hormones and thyromimetics on the liver
Article references thyroid hormone regulation in various contexts, including metabolic control, liver disease, and cancer. It highlights the roles of thyroid hormone receptors, deiodinases, and transporters, and discusses the therapeutic potential of thyromimetics in treating conditions like non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma.
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
Immunovant reports positive batoclimab trial results in Graves’ disease, with 76% response rate. IMVT-1402, another candidate, moves closer to pivotal trial. Batoclimab shows 56% ATD-Free Response and is also being evaluated for thyroid eye disease and CIDP.
Related Clinical Trials:
Duke professor's research leads to first drug for type of liver disease
The FDA approved resmetirom, a drug for metabolic dysfunction-associated steatohepatitis (MASH), developed by Duke professor Paul Yen. Resmetirom targets MASH, a liver disease linked to obesity, affecting 115 million globally. Yen's research, focusing on thyroid hormones, led to the drug's development, aiming to prevent severe complications like cirrhosis and cardiovascular disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath